Testosterone Replacement Therapy in Older Male Subjective Memory Complainers: Double-Blind Randomized Crossover Placebo-Controlled Clinical Trial of Physiological Assessment and Safety

• DOI: 10.2174/1871527314666150429112112
• Publication Date: 2015-05-28T10:30:28Z
• Authors: Prita Asih; Eka Wahjoepramono; Vilia Aniwiyanti; Linda Wijaya; Karl Ruyck; Kevin Taddei; Stephanie Fuller; Hamid Sohrabi; Satvinder Dhaliwal; Giuseppe Verdile; Malcolm Carruthers; Ralph Martins
• Keywords: Crossover study

Testosterone replacement therapy (TRT) has been investigated in older men as a preventative treatment against Alzheimer's disease and dementia. However, previous studies have contradictory. We assessed TRT physiological effects 44 (aged 61 ± 7.7 years) with subjective memory complaints using double blind, randomized, crossover, placebo-controlled study. Participants were randomized into 2 groups, one group received transdermal testosterone (50 mg) daily for 24 weeks, followed by 4 week wash-out period, then weeks of placebo; the other reverse treatment. Blood evaluation revealed significant increases total testosterone, free (calculated) dihydrotestosterone, decrease luteinizing hormone levels (p<0.001) following TRT. Although there red blood cell counts, hemoglobin prostate specific antigen TRT, they remained within normal ranges. No differences plasma amyloid beta, estradiol, sex binding globulin, insulin levels, body fat percentage, or mass index detected. This is first carefully controlled study that influence Indonesian on biomarkers linked to dementia risk. Our suggests safe well-tolerated this cohort, yet longitudinal larger cohorts are needed assess further, establish whether reduces Keywords: Aging, disease, dementia, hormone, plasma.